AbbVie Reports Promising Phase 3 Clinical Trial Results

AbbVie (ABBV), in cooperation with Neurocrine Biosciences, Inc. (NBIX), announced detailed results from two phase 3 clinical trial extension studies on November 1. The studies were analyzing the long-term efficacy and safety of Elagolix, a drug for the managing the pain associated with endometriosis. The results showed no increased safety concern after twelve months along with significant pain reduction in patients.


Rocket Tickers received the news and sent an alert at 12:00. The next trade was for $91.37. The stock price increased to over $93 during the day before falling back a little near the close. The stock price, however, continued to trend up over the next few trading sessions before closing at $95.70 on November 8.

Visit the Knowledge Center for more information about clinical trials and how to trade them.

Subscribe here if you would like to start receiving these signals in real-time and start trading!